Our lead drug candidate, Ruvembri, is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, we believe Ruvembri stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity…
Details
PIPELINE SARCOPENIA (SARA CLINICAL PROGRAM) Sarcopenia is an age-related degeneration of skeletal muscle characterized by a loss of muscle mass strength, balance and the ability to stand and/or walk. Sarcopenia leads to mobility disability in the elderly (³65 years), resulting in a loss of independence, increased risk of adverse health events, such as falls, which…
DetailsWe specialize in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients with COVID-19. Our small molecules are aimed at stimulating biological resilience and are developed through a drug discovery platform based on…
Details
Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19. Our small molecules are aimed at stimulating biological resilience and are developed through…
Details
Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19. Click here Update study – All invest securities In French – Document published on…
Details